Leah Molloy

HCV Rx

Pharmacological analysis for the HCV specialist.

HCV Rx

Targeting the HCV Genome: A Four-Drug Fixed-Dose Regimen

HCV Next, March 2015
The latest approval for a new fixed-dose regimen of ombitasvir, paritaprevir, dasabuvir and ritonavir indicated for the treatment of hepatitis C…
HCV Rx

One-A-Day: Deconstructing the Single-Tablet Regimen for HCV Genotype 1

HCV Next, January
The past year has been very important for the field of hepatitis C virus pharmacology, starting with the late-2013 approvals of the novel…
HCV Rx

A Look at Drug Cost, Financial Assistance Opportunities

HCV Next, October
Leah Molloy, PharmD
New direct-acting antiviral drugs have been widely embraced as more effective and less toxic treatment options for patients with hepatitis C virus…
HCV Rx

Challenges with Pharmacotherapy of HCV/HIV Coinfection

HCV Next, September
Leah Molloy, PharmD
Hepatitis C virus infection is common among individuals already infected with HIV, affecting about one-third of patients. Experts anticipate this…
HCV Rx

Simeprevir: A New NS3/4A Protease Inhibitor

HCV Next, March/April
Leah Molloy, PharmD
Several novel direct-acting antivirals are currently under development in the rapidly evolving field of hepatitis C virus treatment. The newest…
HCV Rx

Sofosbuvir: A Novel Polymerase Inhibitor

HCV Next, January/February
Leah Molloy, PharmD
Historically, the mainstay of treatment for chronic infection with hepatitis C virus has been the traditional regimen of oral ribavirin combined with…
HCV Rx

Managing Side Effects of HCV Treatment

HCV Next, May/June
Leah Molloy, PharmD
Advances in hepatitis C virus therapy have brought forth new antiviral agents that are significantly less toxic than the traditional treatment…